The Study Of Clinical Application Of DC-CIK Combined With Chemotherapy On Advanced Non-small Cell Lung Cancer

Objective:Evaluation of clinical efficacy about advanced non-small cell lung cancer patients with the treatment of DC-CIK combined with chemotherapy(Gemcitabine+Cisplatin). Methods:85non-small cell lung cancer patients confirmed by pathology or cytology were enrolled into two groups in the Oncology Department of Haikou people’s Hospital:42cases received the treatment of DC-CIK combined with GP chemotherapy (immuno-chemotherapy group), meanwhile43cases used GP chemotherapy alone(chemotherapy group). Then the difference between two groups was observed in DCR, ORR, quality of life, toxicity, PFS, OS; the peripheral blood lymphocyte subsets and immune cell phenotypic were analyzed in immuno-chemotherapy group. Results:DCR in two groups is respectively85.7%and76.7%(P>0.05), ORR is35.7and30.2%(P>0.05).(2) The median PFS of immune-chemotherapy group and the chemotherapy group is7.0months and5.0months(P<0.05). The median OS is14.0months and12.0months respectively (P>0.05).(3) Total increase rate of the quality of life in two groups is90.5%and69.8%according to Karnofsky score(P<0.05). The Clinical symptoms of patients such as fatigue, anepithymia, and somnipathy are significantly improved in immuno-chemotherapy group than in chemotherapy group(P<0.05).(4) The toxicity of two groups is similar, mainly in the bone marrow suppression,nausea and vomiting(P>0.05). There were only three patients got a fever in the immuno-chemotherapy group, the occuring rate is7.6%,and no serious adverse reactions are discovered.(5) The T cell percentage,CD4+cell percentage and CD4+/CD8+ratio are significantly increased after treatment than before treatment in immuno-chemotherapy group (P<0.05).(6) The number of phenotypic expression of DC and CIK in immuno-chemotherapy group is significantly increased after cultured in vitro. Conclusion:autologous imumune cells DC-CIK combined with chemotherapy treatment in advanced non-small cell lung cancer can not only prolong the patient’s progression-free survival, But also improve the patient’s suppressed state of immune function, improve the patient’s quality of life, and reduce adverse reactions;the number of phenotypic expression of DC and CIK is significantly increased after cultured in vitro. Figures4,tables6,references59.